BusinessTonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSDBy Nasdaq OMXMay 22, 2017, 8:07 PM UTC
BusinessTonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSDBy Nasdaq OMXMay 22, 2017, 8:07 PM UTC
BusinessTonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSDBy Nasdaq OMXMay 22, 2017, 8:07 PM UTC
BusinessData from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association CongressBy Nasdaq OMXMay 18, 2017, 10:03 AM UTC
